A5090306202- Breast Cancer Treatment Studies
- Brain Metastases and Treatment
- Glioma Diagnosis and Treatment
- Advanced Radiotherapy Techniques
- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Management of metastatic bone disease
- Meningioma and schwannoma management
- Cancer Diagnosis and Treatment
- Myasthenia Gravis and Thymoma
- Cancer Treatment and Pharmacology
- Head and Neck Cancer Studies
- Pelvic and Acetabular Injuries
- Effects of Radiation Exposure
- Cancer Risks and Factors
- HER2/EGFR in Cancer Research
- Endometrial and Cervical Cancer Treatments
- PARP inhibition in cancer therapy
- Oral health in cancer treatment
- Immunotherapy and Immune Responses
- Advances in Oncology and Radiotherapy
- Advanced Breast Cancer Therapies
- Multiple and Secondary Primary Cancers
- Radiation Therapy and Dosimetry
Institut Curie
2015-2025
Monash Health
2024
Institut du Thorax
2021-2024
Carnegie Mellon University
2024
Université Paris Sciences et Lettres
2020-2024
Institut Gustave Roussy
2015-2017
Helsinki University Hospital
2017
Pitié-Salpêtrière Hospital
2014-2015
Sorbonne Université
2014-2015
Abstract Triple‐negative breast cancer (TNBC) cells are sensitive to PARP1 inhibitors in vitro. The combination of Olaparib and radiotherapy for TNBC is currently evaluated the Phase I RADIOPARP trial. a monocentric prospective open‐label dose‐escalation trial evaluating patients with inflammatory, locoregionally advanced or metastatic disease, residual disease after neoadjuvant chemotherapy. was orally given at increasing dose levels (50, 100, 150 200 mg twice day [BID]); consisted 50 Gy...
The current standard-of-care management of locally advanced triple negative breast cancer (TNBC) is based on neoadjuvant chemo-immunotherapy with pembrolizumab, surgery, radiation therapy (RT), and adjuvant pembrolizumab. However, the safety combining pembrolizumab RT has never been evaluated. This study evaluated tolerance profile concurrent in patients TNBC.
Triple-negative breast cancer (TNBC) patients with residual disease after neoadjuvant therapy face a high risk of locoregional recurrence, particularly when homologous recombination deficiency (HRD) is present. HRD tumors, characterized by impaired double-strand break repair, are theoretically sensitive to PARP inhibitors through synthetic lethality. This phase I trial (XXXXX) evaluated the long-term safety and potential radiosensitizing effects Olaparib combined radiotherapy in TNBC...
Objectives: Recent DESTINY-Breast trials have demonstrated trastuzumab deruxtecan’s effectiveness in HER2-positive and HER2-low metastatic breast cancer. However, safety concerns remain regarding its combination with radiation therapy (RT). The purpose of this work is to assess the toxicity profile combining deruxtecan RT patients cancer address these concerns. Methods: We conducted a retrospective study which included treated at Institut Curie Paris between November 2020 January 2024....
The combination of pertuzumab and trastuzumab dual HER2 blockade with concomitant curative dose locoregional breast radiotherapy in patients metastatic cancer is an important part treatment strategy.This was a retrospective study conducted at the Institut Curie on all treated concomitantly pertuzumab/trastuzumab radiotherapy. Toxicity evaluated according to NCICTCAEv4.0. Overall survival, progression-free survival recurrence-free were who initially well controlled by chemotherapy, for whom...
AbstractPurpose Ultra-hypofractionation breast radiotherapy is a safe alternative to moderate hypofractionation. This study reports the results of two ultrahypofractionated regimens used in clinical practice high-volume center terms efficacy and tolerance.Methods we included all patients treated an adjuvant setting with five fractions after conserving surgery (BCS), for histologically-confirmed invasive or situ carcinoma. Radiotherapy BCS were either 5-week schedule 5 weekly 5,7 Gy one-week...
Abstract BACKGROUND AND PURPOSE: The current standard-of-care management of locally advanced triple negative breast cancer (TNBC) is based on neoadjuvant chemo-immunotherapy with pembrolizumab, surgery, radiotherapy and adjuvant pembrolizumab. However, the safety combining pembrolizumab has never been evaluated. This study evaluated tolerance profile concurrent (P) (RT) in TNBC patients. METHODS: bicentric ambispective included first prospectively registered patients non-metastatic treated...